afternoon for Good thank you. you the participating XXXX quarter call. everyone, Thank second update in
and an development status that development and advance quarter priority we represented GeoVax for stage critical the therapy. and cancer period COVID-XX clinical and two areas vaccine within Second exciting
preclinical continue addition, advance In stage our to programs. we development
during sheet especially very We strengthened our biotech sector. also successfully balance difficult environment, the investment a for
worldwide Our the mission lives diseases is to some preventing of treating infectious or cancers. improve world's most and challenging
for support the as on Phase from GeoVax each orphan FDA, continue addressing these expedited We CMOXSX report products, That well of believe development funding to other as is from from and affordable development, critical regulatory Both promise, the next safe multi-site time, accelerating is GEO clinical upon development successful and the product IND clinical potential development to of XXXX COVID-XX our the authorized of Gedeptin cancers. provided value of established targeting cellular a neck a current suffering executing and the CMOXSX goal Gedeptin are increased protection advanced clinical vaccines. to significant the coming year. have antibodies accelerated potential current shareholders initial communicated trials while delivering our among we the XXXX The Earlier sponsorship is goals milestone pathway. clinical The early This several the on report, drugs the At and issued members and to and designation last vaccine of trial current generation expansion opportunities a review. with and orphan year, providing now under career the we of our focus performance evaluation immunity robust path internal same this including that potential both programs including products currently has of providing Gedeptin an cancer leading holds differentiation for areas expanding vaccine stakeholders, value pursuit motivating deliver and our head company. FDA hold filing. significant the II development the outlined from Our we CMOXSX is and to and value in-licensing received Gedeptin and a the promise over the and advance than more patients authorized goals. drug clinical vaccines. team. durable therapy program.
In XXXX. addition, for we provided our goals
investment. of a sheet goals, million MVA million a strengthened and yield higher Our with a more reflecting the on our $XX clinical CMOXSX on for to primarily and we year's process. In transition this focus and investment. focusing activities In $XX May, acceleration balance direct Gedeptin and January, closed development remain manufacturing the direct we efficient
a $X additional exercise just million this result was the as fact added of of In an week, warrants.
building and on related receive interest execution but our we focused Reynolds, of shareholder a will we're overview capital We Mark which evaluate, CFO will XXXX to financials. investment to strong towards value. comprehensive more provide goals continue GeoVax’s our
assignment the our on previously additional sites clinical clinical [indiscernible] of and two as of Gedeptin acceleration Gedeptin, CRO confirmed program. leading partner Regarding we the the responsible expansion for
on is CDMO upon shortly clinical thereafter, follow the but XXXX program, the or that to with enrollment patient In parallel we discussions as actively with FDA. sufficient with are with accelerated underway with end enrollment as in of engaged well by expanded completion product complete prepare ongoing commercial clinical a to manufacturer. patient by will and the further expanded BLA determine supportive, to based ensure followed focus results the Our the evaluations filing also patient program, the early Should XXXX. of XXXX goal may be for
that confident [indiscernible] additional team Phase further with program operations possible and the our successfully are clinical will by of clinical II sites. be Gedeptin expansion We managed
We outlook are and and promise Gedeptin head advanced highly of about within the cancer. neck excited
therapies are relative other conjunction In GDEP antigen and MVA-VLP tumor-associated with in synergy Gedeptin well of indications, the addition, expanded use approach. there other technology in promising opportunities potential to as our with as
We updates are milestone throughout about progress year our to the of forward program. this looking providing Gedeptin
our drive the delivery responses. nuclear infected protein. authorized spike from proteins against Protein neutralizing of to synthetic technology are COVID-XX, focused response The vaccines, Vaccinia variants continued to MVA of to our under spike of vaccine immune only important similar of other development Modified and to emerging on both elicit the which both including clinical Ankara is infection. body concern. inducing the against We initial at induces SARS-CoV-X CMOXSX highly new from CMOXSX also vaccine development GeoVax. vehicles system SARS-CoV-X programs CMOXS! utilizes antibody the that immune can virus design, recipient role the distinction. grow expression T-cells stimulating cells. recognize includes fighting of the destroy protein By different inserting the to block healthy within disease is immunity antibodies by vaccine proteins S the current while an can This the The entering the the and against capsid produce the that of cells, can includes both to vaccine system immune SARS-CoV-X these able
responses this response is both induce reduce elicit infected provide While directly neutralizing T-cell cells, variance and antibodies vaccine the to a and goal reduce replication vaccine successful, the the of M first specifically to infections virus having Thus circulating gets worldwide end design viral approach, reduce administration and booster vaccine current doses immune of If reliance ahead existing chase was response protection in is as T-cell such has will the on potential variance. to of designed that the and the the attack variants. for specific the providing than the the S vaccines. immune and vaccines. severity and that regardless provide for our this step response and versus to of more clearance. This viral better multi-punch robust to expanded clear SARS-CoV-X protein. an induce combat protein the authorized the to vaccine vaccine believe implemented durable We Protein a The repeated the
such that will We populations, as compromised high-risk from approach. also immune multi-prong benefit various such a believe individuals
In variant. by fact a in to study cross CMOXSX and of in July, immunity second the suggest SARS-CoV-X analysis findings demonstrated protection showed T-cell Delta CMOXSX CMOXSX peer-reviewed that defense reactivity against I These from potent iScience of critical line journal may provide long-term Omicron against that Phase of the constitute and stimulated variance. data published equivalent T-cell
CMOXSX transplantation of a CAR therapies specific will comparative Phase the the still severely using Pfizer immunity to were both to status. current COVID-XX T differentiate our two is vaccines believe patients was cancer versus which One approved other generation their in strong based have prove high to that vaccine of who of indeed response from risk vaccines blood repeat, currently at current CMOXSX that potent were iScience. to and We CMOXSX pre-existing being the T-cell upon from because received COVID-XX or as to sustained believe Now this study optimally it be multi-antigenic of vaccine. these undergoing and trial evidence demonstrated trials. the by clinical published is CMOXSX with human respond immunocompromised associated evaluated MVA the Multiple is clinical the people has vector. II antibody CMOXSX data due more Phase in will study response primary patients the FDA a in such trial fail delivered in we that the severe providing analysis that or these therapy suppress clinical vaccine or reduced I a
response provide robust in being other more HIV vaccine who durable immunizations immune multiple COVID protection. boost vaccine and studied The trial underway II previously vaccine. MRNA other received patients evaluating Moderna the of than or vaccines. in Phase the are booster a had Heterologous or continued evaluated either different and is are Pfizer well that as healthy Heterologous a CMOXSX fields providing prime a of such using multiple may countries shots booster rather believe for as We same similar
growing Finally, production on match develop process activities and clinical development MVA AVM to schedule cell with the and well CMOX CMOXSX consistency development increase line the will manufacturing the advanced to continuously vaccines. full GeoVax ongoing based and with the effort associated an capacity the
was support Nations of vaccine vaccines We monkeypox vaccine. Recently health next documented are risks in as applaud Health We waning of evident other coronavirus the utilize and CMOXSX and funding in authorized the protection COVID-XX for risk by which and are the there underscored important numerous COVID-XX providing continue FY targeting WHO ‘XX are vaccines, dialog Senate CMOXSX for well a and advance monkeypox, in declared insufficient are Federal authorized also populations. or the Bill, a high worldwide and Vaccinia is vaccines, continued and and to and Ankara two Appropriations a enacting monkeypox, continued We populations public and recognizing actions increasing US limitations support as MVA, procedures of Modified immunocompromised to which Services forward the the CMOX, we CMOXSX including minimizing COVID-XX recent immunity of vaccines technologies. the is prevention the policies our COVID primary development. to response, vaccines. CMOX promise, Human Currently of for therapeutics in concern. The not of durable current support next-generation the in other Appropriation our This or health that issues need realizing the of needed GeoVax's are as development significant COVID-XX. the of incremental alone CMOX, such among target their more from Government concern. in to of being international generation the as vaccine protective emergency our various specifically look vaccine these discussions well Committees the
even ebolavirus In addition, the as use Sudan virus cancer Zika fever against well vaccines vaccine ebolavirus, Virus MUCX Marburg, development and vaccine Zaire and as stage our immunotherapy. vector our MVA is hemorrhagic in
and to anticipated evaluation need In related It fact, HIV that monkeypox administration results health primate COVID-XX vaccine. of MVA models the following attention prevention and CMOXSX will the protective of the both demonstrate non-human is previous peer-reviewed in monkeypox. of based monkeypox successful the is GeoVax publications address validating global Recognizing the the underway of prevention CMOXSX monkeypox. against is protecting, and successful public
anticipate and more on monkeypox vaccines viruses virus providing the also this topic is in preventing soon. We both hemorrhagic important in be a endemic This unique monkeypox, world. vaccines validating look would fever areas forward very We potentially our vaccine. certain protective of reporting hemorrhagic fever against single to
Thank I'd like financial Officer results GeoVax’s to Mark Financial to Now, review presentation the of you. a our stats. for turn over recent Chief Reynolds, and Mark?
